IRWD - Ironwood Pharmaceuticals, Inc. Stock Price and Quote

IRWD [NASD]

Healthcare | Drug Manufacturers - Specialty & Generic | USA

Index	-	P/E	10.80	EPS (ttm)	0.96	Insider Own	1.40%	Shs Outstand	153.32M	Perf Week	-1.87%
Market Cap	1.58B	Forward P/E	10.12	EPS next Y	1.03	Insider Trans	-15.13%	Shs Float	150.89M	Perf Month	-7.00%
Income	175.10M	PEG	-	EPS next Q	0.25	Inst Own	-	Short Float / Ratio	10.82% / 7.82	Perf Quarter	-15.61%
Sales	410.60M	P/S	3.85	EPS this Y	-70.00%	Inst Trans	-3.31%	Short Interest	16.33M	Perf Half Y	1.16%
Book/sh	4.25	P/B	2.45	EPS next Y	-1.34%	ROA	16.70%	Target Price	12.75	Perf Year	-17.14%
Cash/sh	4.33	P/C	2.41	EPS next 5Y	-	ROE	30.50%	52W Range	9.73 - 12.90	Perf YTD	-15.33%
Dividend	-	P/FCF	5.77	EPS past 5Y	35.80%	ROI	16.50%	52W High	-18.68%	Beta	0.97
Dividend %	-	Quick Ratio	30.60	Sales past 5Y	6.60%	Gross Margin	-	52W Low	7.81%	ATR	0.29
Employees	219	Current Ratio	30.60	Sales Q/Q	-8.50%	Oper. Margin	60.90%	RSI (14)	41.82	Volatility	3.49% 2.67%
Optionable	Yes	Debt/Eq	0.61	EPS Q/Q	7.90%	Profit Margin	42.60%	Rel Volume	0.13	Prev Close	10.42
Shortable	Yes	LT Debt/Eq	0.61	Earnings	Feb 16 BMO	Payout	0.00%	Avg Volume	2.09M	Price	10.49
Recom	2.30	SMA20	-1.45%	SMA50	-5.41%	SMA200	-7.23%	Volume	14,532	Change	0.67%

Sep-02-22

Initiated

CapitalOne

Overweight

$15

Apr-22-22

Initiated

Piper Sandler

Overweight

$16

Sep-30-20

Downgrade

Wells Fargo

Overweight → Equal Weight

$14 → $9

Jun-17-20

Initiated

Northland Capital

Outperform

$14

Jul-10-19

Resumed

Credit Suisse

Neutral

Mar-27-19

Upgrade

Morgan Stanley

Underweight → Equal-Weight

Feb-25-19

Upgrade

H.C. Wainwright

Sell → Neutral

$14

Jan-24-19

Upgrade

JP Morgan

Underweight → Neutral

Nov-07-18

Downgrade

JP Morgan

Neutral → Underweight

Nov-07-18

Downgrade

Credit Suisse

Outperform → Neutral

Show Previous Ratings

Mar-22-23 02:53PM	Ironwood Pharmaceuticals, Inc.'s (NASDAQ:IRWD) Fundamentals Look Pretty Strong: Could The Market Be Wrong About The Stock? Simply Wall St.
Mar-14-23 02:56AM	Strength Seen in Xencor (XNCR): Can Its 5.3% Jump Turn into More Strength? Zacks
Mar-02-23 07:09AM	Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) Shares Could Be 40% Below Their Intrinsic Value Estimate Simply Wall St.
Feb-27-23 04:01PM	Ironwood Pharmaceuticals to Participate in Upcoming Investor Conferences Business Wire
Feb-20-23 07:40AM	Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) Q4 2022 Earnings Call Transcript Insider Monkey
11:11AM	Loading…
Feb-17-23 11:11AM	Ironwood (IRWD) Q4 Earnings Miss, Linzess Volume Increases Zacks
Feb-16-23 08:35AM	Ironwood Pharmaceuticals (IRWD) Misses Q4 Earnings and Revenue Estimates Zacks
07:00AM	Ironwood Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Results Business Wire
Feb-15-23 11:09AM	Drug/Biotech Stocks Q4 Earnings Due on Feb 16: ALKS, RARE & Others Zacks
Feb-14-23 10:00AM	BioCryst Pharmaceuticals (BCRX) Expected to Beat Earnings Estimates: Can the Stock Move Higher? Zacks
07:20AM	Ironwood (IRWD) Gets FDA Priority Tag for Linzess sNDA Zacks
Feb-13-23 07:30AM	Ironwood Pharmaceuticals Announces FDA Filing Acceptance and Priority Review of Supplemental New Drug Application for LINZESS® (linaclotide) for Functional Constipation in Children and Adolescents Ages 6-17 Years-Old Business Wire
Feb-10-23 07:40AM	15 Small Innovative Companies According to the Media Insider Monkey
Feb-09-23 10:01AM	Ironwood Pharmaceuticals (IRWD) Earnings Expected to Grow: Should You Buy? Zacks
Feb-04-23 09:40AM	3 No-Brainer Stocks to Buy Right Now for Less Than $25 Motley Fool
04:01PM	Loading…
Feb-02-23 04:01PM	Ironwood Pharmaceuticals to Host Fourth Quarter and Full Year 2022 Investor Update Call Business Wire
Jan-23-23 11:07AM	12 Most Undervalued Pharma Stocks To Buy According To Hedge Funds Insider Monkey
Jan-16-23 05:36AM	Ironwood Pharmaceuticals (NASDAQ:IRWD) shareholders are up 3.7% this past week, but still in the red over the last five years Simply Wall St.
Jan-09-23 06:00AM	Ironwood Pharmaceuticals Provides Update on FY 2022 Financial Guidance and Announces FY 2023 Financial Guidance Business Wire -10.99%
Jan-04-23 04:01PM	Ironwood Pharmaceuticals to Present at the 41st Annual J.P. Morgan Healthcare Conference Business Wire
Dec-09-22 11:30AM	Catalyst (CPRX) Up 8.9% Since Last Earnings Report: Can It Continue? Zacks
Nov-22-22 04:01PM	Ironwood Pharmaceuticals to Participate in the Piper Sandler 34th Annual Healthcare Conference Business Wire
Nov-09-22 07:47AM	Ironwood Pharmaceuticals Third Quarter 2022 Earnings: Misses Expectations Simply Wall St.
Nov-04-22 12:13PM	Ironwood's (IRWD) Q3 Earnings Beat, Linzess Volume Grows Zacks
Nov-03-22 08:35AM	Ironwood Pharmaceuticals (IRWD) Beats Q3 Earnings Estimates Zacks
07:01AM	Ironwood Pharmaceuticals Reports Strong Third Quarter 2022 Results; Maintains Full Year 2022 Financial Guidance Business Wire
Oct-20-22 04:01PM	Ironwood Pharmaceuticals to Host Third Quarter 2022 Investor Update Call Business Wire
01:43PM	2 Health Care Stocks That Fit Graham's Lost Formula GuruFocus.com
Sep-25-22 09:48AM	Will Weakness in Ironwood Pharmaceuticals, Inc.'s (NASDAQ:IRWD) Stock Prove Temporary Given Strong Fundamentals? Simply Wall St.
Sep-07-22 10:02AM	Ironwood's (IRWD) Functional Constipation Study in Kids Succeeds Zacks
09:26AM	Loading…
Sep-06-22 09:26AM	Ironwood's Constipation Drug Shows Efficacy In Pediatric Patients Benzinga
07:00AM	Ironwood Pharmaceuticals Reports Positive Topline Data from Phase III Trial of LINZESS® (linaclotide) in Pediatric Patients Aged 6-17 with Functional Constipation Business Wire
Sep-01-22 04:01PM	Ironwood Pharmaceuticals to Present at the 2022 Wells Fargo Healthcare Conference Business Wire
Aug-29-22 08:22AM	These 4 Measures Indicate That Ironwood Pharmaceuticals (NASDAQ:IRWD) Is Using Debt Safely Simply Wall St.
Aug-08-22 01:25PM	The 3.7% return this week takes Ironwood Pharmaceuticals' (NASDAQ:IRWD) shareholders three-year gains to 25% Simply Wall St.
Aug-05-22 11:45AM	Ironwood (IRWD) Q2 Earnings Miss, Keeps 2022 Sales Guidance Zacks
Aug-04-22 08:45AM	Ironwood Pharmaceuticals (IRWD) Misses Q2 Earnings and Revenue Estimates Zacks
07:00AM	Ironwood Pharmaceuticals Reports Second Quarter 2022 Results; Maintains Full Year Guidance Due to Continued Strength of LINZESS® Prescription Demand Business Wire
Jul-21-22 04:01PM	Ironwood Pharmaceuticals to Host Second Quarter 2022 Investor Update Call Business Wire
Jun-03-22 07:21PM	Keurig Dr Pepper, VICI Properties and ON Semiconductor Set to Join S&P 500; Others to Join S&P MidCap 400, and S&P SmallCap 600 PR Newswire
May-25-22 07:30AM	Ironwood Presents New Data Demonstrating Potential of IW-3300 for Visceral Pain at Digestive Disease Week® (DDW) 2022 Business Wire
May-09-22 08:00AM	Ironwood Pharmaceuticals to Present New IW-3300 and Linaclotide Data at Digestive Disease Week® 2022 Business Wire
May-06-22 10:24AM	Ironwood (IRWD) Q1 Earnings Miss, Linzess Growth Continues Zacks
May-05-22 08:45AM	Ironwood Pharmaceuticals (IRWD) Q1 Earnings Miss Estimates Zacks
07:00AM	Ironwood Pharmaceuticals Reports First Quarter 2022 Results; Maintains Full Year 2022 Financial Guidance Business Wire
Apr-28-22 03:02PM	Ironwood Pharmaceuticals (IRWD) Earnings Expected to Grow: What to Know Ahead of Next Week's Release Zacks
Apr-21-22 04:01PM	Ironwood Pharmaceuticals to Host First Quarter 2022 Investor Update Call Business Wire
Apr-14-22 05:35AM	Strength Seen in BioCryst (BCRX): Can Its 15.2% Jump Turn into More Strength? Zacks
Mar-17-22 10:45AM	Top Pharmaceutical Stocks for Q2 2022 Investopedia
Mar-02-22 07:30AM	Ironwood Pharmaceuticals to Present at Upcoming Investor Conferences Business Wire
Feb-18-22 10:54AM	Ironwood (IRWD) Q4 Earnings Miss, Linzess Volume Grows Zacks
Feb-17-22 07:00AM	Ironwood Pharmaceuticals Reports Fourth Quarter and Full Year 2021 Results; LINZESS® (linaclotide) Achieves Blockbuster Status as U.S. Net Sales Exceed $1 Billion in 2021 Business Wire
Feb-16-22 09:11AM	Medical Stocks' Q4 Earnings on Feb 17: RGEN, IRWD & More Zacks
Feb-15-22 10:14AM	10 Cheap Pharmaceutical Stocks For 2022 Insider Monkey
Feb-10-22 09:35AM	Is Ironwood Pharmaceuticals (IRWD) a Suitable Stock for Value Investors? Zacks
Feb-03-22 07:30AM	Ironwood Pharmaceuticals to Host Fourth Quarter and Full Year 2021 Investor Update Call Business Wire
Jan-21-22 05:38PM	Denali Advisors Llc Buys Sanmina Corp, Mueller Industries Inc, BlueLinx Holdings Inc, Sells , ... GuruFocus.com
Jan-10-22 07:20AM	Ironwood Pharmaceuticals Provides Update on FY 2021 Financial Guidance and Announces FY 2022 Financial Guidance Business Wire
Jan-05-22 07:30AM	Ironwood Pharmaceuticals to Present at the 40th Annual J.P. Morgan Healthcare Conference Business Wire
Dec-24-21 06:38AM	Putnam Variable Trust Buys Intuit Inc, Bank of America Corp, Advanced Micro Devices Inc, Sells ... GuruFocus.com
Dec-23-21 11:15PM	Ironwood Pharmaceuticals Inc (IRWD) CEO Thomas A Mccourt Sold $528,591 of Shares GuruFocus.com
Dec-11-21 03:16PM	Here is What Hedge Funds Think About Ironwood Pharmaceuticals, Inc. (IRWD) Insider Monkey
Dec-01-21 07:30AM	Ironwood Pharmaceuticals Appoints Sravan K. Emany as Chief Financial Officer Business Wire
Nov-05-21 10:35AM	Ironwood (IRWD) Q3 Earnings Top, Sales Hurt by Lower Price Zacks
Nov-04-21 02:01PM	Ironwood Pharmaceuticals, inc (IRWD) Q3 2021 Earnings Call Transcript Motley Fool
09:55AM	Ironwood Pharmaceuticals (IRWD) Q3 Earnings Surpass Estimates Zacks
07:15AM	Ironwood Pharmaceuticals Reports Third Quarter 2021 Results and Provides Corporate Development Update Business Wire
07:00AM	Ironwood Pharmaceuticals Expands Pipeline by Signing an Option Agreement to Acquire an Exclusive License with COUR Pharmaceuticals to Develop and Commercialize CNP-104 for the Treatment of Primary Biliary Cholangitis (PBC) in the U.S. Business Wire
Oct-25-21 07:30AM	More than 90% of Surveyed IBS-C Patients Who Had an ER Visit or Hospitalization in the Past Year Identified Abdominal Pain as a Symptom That Led to the Visit, According to Data Announced by Ironwood Pharmaceuticals at ACG 2021 Business Wire
Oct-21-21 07:00AM	Ironwood Pharmaceuticals to Host Third Quarter 2021 Investor Update Call Business Wire
Oct-18-21 04:04AM	Hedge Fund Sentiment Is Stagnant On Ironwood Pharmaceuticals, Inc. (IRWD) Insider Monkey
Oct-05-21 12:47PM	10 Best Stocks Under $15 According to Billionaire Michael Price Insider Monkey
Oct-04-21 01:00AM	Is Companhia Brasileira de Distrib. (CBD) A Good Stock To Buy? Insider Monkey
Oct-01-21 10:13AM	Bausch's (BHC) NOV03 for Dry Eye Disease Meets Study Goal Zacks
Sep-08-21 11:34AM	Citius (CTXR) Acquires Dr. Reddy's License for NHL Therapy Zacks
Sep-03-21 10:10AM	Takeda (TAK) Hematology Candidate Fails in Late-Stage Study Zacks
Sep-02-21 07:30AM	Ironwood Pharmaceuticals to Participate in Upcoming September Investor Conferences Business Wire
Aug-26-21 11:04AM	Amneal (AMRX) Parkinson's Candidate Successful in Pivotal Study Zacks
07:00AM	Ironwood Pharmaceuticals Announces FDA Approval of Revised LINZESS® (linaclotide) Label Business Wire
04:58AM	Ironwood Irritable-Bowel Drug Gets Revised FDA Warning Label TheStreet.com
Aug-06-21 11:52AM	Ironwood's (IRWD) Q2 Earnings Beat, 2021 Guidance Raised Zacks
Aug-05-21 04:01PM	Ironwood Pharmaceuticals, inc (IRWD) Q2 2021 Earnings Call Transcript Motley Fool
07:00AM	Ironwood Pharmaceuticals Reports Strong Second-Quarter 2021 Results, Raises Full-Year Guidance Business Wire
Aug-04-21 12:10PM	Why Ironwood (IRWD) Could Beat Earnings Estimates Again Zacks
Aug-03-21 07:30AM	Ironwood Pharmaceuticals Appoints John Minardo as Chief Legal Officer Business Wire
Jul-29-21 03:05PM	Ironwood Pharmaceuticals (IRWD) Reports Next Week: Wall Street Expects Earnings Growth Zacks
09:15AM	Ironwood (IRWD) Hits 52-Week High, Can the Run Continue? Zacks
Jul-23-21 04:47PM	Tilray (TLRY) to Report Q4 Earnings: What's in the Cards? Zacks
Jul-22-21 04:01PM	Ironwood Pharmaceuticals to Host Second Quarter 2021 Investor Update Call Business Wire
Jul-21-21 03:25AM	We Think Ironwood Pharmaceuticals (NASDAQ:IRWD) Can Manage Its Debt With Ease Simply Wall St.
Jul-12-21 03:39PM	Is Ironwood Pharmaceuticals, Inc. (IRWD) A Good Stock To Buy? Insider Monkey
Jun-16-21 07:45AM	Ironwood Pharmaceuticals Announces That The American Journal of Gastroenterology Publishes Full Results from Positive LINZESS® (linaclotide) Phase IIIb Trial in Adults with Irritable Bowel Syndrome with Constipation (IBS-C) Business Wire
Jun-15-21 03:52AM	A Look At Ironwood Pharmaceuticals' (NASDAQ:IRWD) Share Price Returns Simply Wall St.
Jun-07-21 04:01PM	Ironwood Pharmaceuticals Announces Leadership Updates Business Wire
May-26-21 04:01PM	Ironwood Pharmaceuticals Announces Agreement with Teva Involving LINZESS® (linaclotide) 72 mcg Dosage Strength Business Wire
May-24-21 08:00AM	More Than a Third of Surveyed IBS-C Patients Reported That Their Symptoms Worsened During COVID-19 According to New Survey Findings Presented by Ironwood Pharmaceuticals at Digestive Disease Week® (DDW) Business Wire
May-17-21 08:30AM	Ironwood Pharmaceuticals to Present New Linaclotide Data and Unveil Findings From GI Disease Surveys at Digestive Disease Week® 2021 Business Wire
May-12-21 10:03AM	Minerva (NERV) Soars on Promising Schizophrenia Study Data Zacks
May-10-21 06:16AM	Moving Average Crossover Alert: Ironwood Pharmaceuticals (IRWD) Zacks
01:22AM	Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) First-Quarter Results Just Came Out: Here's What Analysts Are Forecasting For This Year Simply Wall St.

Ironwood Pharmaceuticals, Inc., a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. It markets linaclotide, a guanylate cyclase type-C (GC-C) agonist for the treatment of adults suffering from irritable bowel syndrome with constipation or chronic idiopathic constipation under the LINZESS name in the United States, Mexico, Japan, and China, as well as under the CONSTELLA name in the Canada and European countries. The company is also developing IW-3300, a GC-C agonist for the treatment of visceral pain conditions, including interstitial cystitis/bladder pain syndrome and endometriosis; and CNP-104, an immune nanoparticle for the treatment of primary biliary cholangitis. The company has strategic partnerships with AbbVie Inc., AstraZeneca AB, and Astellas Pharma Inc. for the development and commercialization of linaclotide. The company was formerly known as Microbia, Inc. and changed its name to Ironwood Pharmaceuticals, Inc. in April 2008. Ironwood Pharmaceuticals, Inc. was incorporated in 1998 and is headquartered in Boston, Massachusetts.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
MCCOURT Thomas A	Chief Executive Officer	Mar 27	Sale	10.67	46,129	492,196	842,064	Mar 29 04:05 PM
MCCOURT Thomas A	Chief Executive Officer	Mar 03	Sale	11.22	33,756	378,742	647,598	Mar 07 04:05 PM
MCCOURT Thomas A	Chief Executive Officer	Feb 28	Sale	11.31	31,227	353,177	681,354	Mar 01 06:22 PM
Rickard Jason	SVP, Chief Operating Officer	Feb 28	Sale	11.31	17,429	197,122	332,648	Mar 01 06:24 PM
Shetzline Michael	CMO,SVP,Head-Res&Drug	Feb 28	Sale	11.31	9,854	111,449	261,586	Mar 01 06:21 PM
John Minardo	Chief Legal Officer	Feb 28	Sale	11.31	3,415	38,624	133,738	Mar 01 06:19 PM
Silver Ronald	Principal Accounting Officer	Feb 28	Sale	11.31	3,049	34,484	98,491	Mar 01 06:25 PM
Davis Andrew	SVP, Chief Business Officer	Feb 28	Sale	11.31	1,822	20,607	151,396	Mar 01 06:17 PM
MCCOURT Thomas A	Chief Executive Officer	Feb 27	Sale	11.41	30,004	342,346	712,581	Mar 01 06:22 PM
Rickard Jason	SVP, Chief Operating Officer	Feb 27	Sale	11.41	16,746	191,072	350,077	Mar 01 06:24 PM
Shetzline Michael	CMO,SVP,Head-Res&Drug	Feb 27	Sale	11.41	9,468	108,030	271,440	Mar 01 06:21 PM
John Minardo	Chief Legal Officer	Feb 27	Sale	11.41	3,282	37,448	137,153	Mar 01 06:19 PM
Silver Ronald	Principal Accounting Officer	Feb 27	Sale	11.41	2,929	33,420	101,540	Mar 01 06:25 PM
Davis Andrew	SVP, Chief Business Officer	Feb 27	Sale	11.41	1,751	19,979	153,218	Mar 01 06:17 PM
MCCOURT Thomas A	Chief Executive Officer	Jan 05	Option Exercise	11.65	110,962	1,292,707	823,402	Jan 09 04:05 PM
MCCOURT Thomas A	Chief Executive Officer	Jan 05	Sale	12.07	110,962	1,339,311	712,440	Jan 09 04:05 PM
Rickard Jason	SVP, Chief Operating Officer	Dec 14	Sale	12.39	27,000	334,530	348,736	Dec 16 04:05 PM
Emany Sravan Kumar	SVP, Chief Financial Officer	Nov 21	Sale	11.56	6,578	76,042	78,422	Nov 23 04:05 PM
Davis Andrew	SVP, Chief Business Officer	Nov 21	Sale	11.56	3,335	38,553	154,213	Nov 23 04:05 PM
Silver Ronald	Principal Accounting Officer	Nov 21	Sale	11.56	682	7,884	104,469	Nov 23 04:05 PM
MCCOURT Thomas A	Chief Executive Officer	Oct 03	Sale	10.41	18,899	196,739	712,440	Oct 05 04:05 PM
MCCOURT Thomas A	Chief Executive Officer	Sep 01	Sale	10.65	26,446	281,650	731,339	Sep 06 04:05 PM
John Minardo	Chief Legal Officer	Aug 15	Sale	11.77	7,330	86,274	140,435	Aug 17 04:05 PM
Silver Ronald	Principal Accounting Officer	Aug 15	Sale	11.77	2,014	23,705	105,151	Aug 17 04:05 PM
Rickard Jason	SVP, Chief Operating Officer	Aug 15	Sale	11.77	994	11,699	375,736	Aug 17 04:05 PM
Currie Mark G	Director	Aug 11	Sale	11.78	70,000	824,600	521,758	Aug 15 04:17 PM
Rickard Jason	SVP, Chief Operating Officer	Aug 09	Option Exercise	11.65	18,041	210,178	394,771	Aug 10 04:06 PM
Rickard Jason	SVP, Chief Operating Officer	Aug 09	Sale	11.75	18,041	211,982	376,730	Aug 10 04:06 PM
Rickard Jason	SVP, Chief Operating Officer	Aug 08	Sale	11.63	29,436	342,456	376,730	Aug 10 04:06 PM
MCCOURT Thomas A	Chief Executive Officer	Aug 01	Sale	11.35	23,229	263,649	757,785	Aug 03 04:05 PM
MCCOURT Thomas A	Chief Executive Officer	Jun 30	Sale	11.58	19,959	231,125	778,922	Jul 05 04:05 PM
Kessler Marla L	Director	Jun 14	Sale	11.65	7,610	88,656	84,148	Jun 16 04:05 PM
Currie Mark G	Director	Jun 07	Option Exercise	11.65	190,383	2,217,962	782,141	Jun 09 05:04 PM
Currie Mark G	Director	Jun 07	Sale	12.01	190,383	2,286,500	591,758	Jun 09 05:04 PM
MCCOURT Thomas A	Chief Executive Officer	May 23	Sale	11.50	36,308	417,542	798,881	May 25 04:05 PM
Rickard Jason	SVP, Chief Operating Officer	May 23	Sale	11.50	13,537	155,676	404,074	May 25 04:05 PM
Shetzline Michael	CMO,SVP,Head-Res&Drug	May 23	Sale	11.50	10,583	121,704	266,245	May 25 04:05 PM
Silver Ronald	Principal Accounting Officer	May 23	Sale	11.50	120	1,380	105,073	May 25 04:05 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

Upgrade your FINVIZ experience